MedTrace Logo

Conventional Vaccine and Intradermal Vaccine Among HIV-infected Young Subjects

NCT02398097 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2015-03-25

No results posted yet for this study

Summary

Several studies have shown poor immune response to conventional influenza vaccines in HIV-infected individuals. This study was conducted expecting the more potent immunogenicity of intradermal vaccine compared with conventional intramuscular vaccine in HIV-infected adults.

Conditions

  • Human Influenza

Interventions

BIOLOGICAL

Agripal

2011/2012 influenza season standard dose trivalent subunit inactivated intramuscular vaccine, single dose

BIOLOGICAL

IDflu9μg

2011/2012 influenza season reduced-content intradermal split vaccine, single dose

BIOLOGICAL

IDflu15μg

2011/2012 influenza season standard-content intradermal split vaccine, single dose

Sponsors & Collaborators

  • Korea University Guro Hospital

    lead OTHER

Principal Investigators

  • Hee Jin Cheong, MD, PhD · Korea University Guro Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2011-12-31
Completion
2012-04-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02398097 on ClinicalTrials.gov